TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
- Conditions
- Hodgkin LymphomaAcute Lymphoblastic Leukemia (ALL)Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)NK-Cell LeukemiaNon Hodgkin Lymphoma (NHL)Juvenile Myelomonocytic Leukemia (JMML)Chronic Myeloid Leukemia (CML)
- Interventions
- Device: CliniMACSBiological: TCRα/β+Biological: CD19+Biological: CD45RA-depleted DLI
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03849651
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03850535
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Acute Myeloid Leukemia (AML) Adult Patients
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Golden Biotechnology Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT03823352
- Locations
- 🇷🇺
City Clinical Hospital n.a. S.P.Botkin, Moscow, Russian Federation
🇷🇺Tula Regional Clinical Hospital, Tula, Russian Federation
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 120
- Registration Number
- NCT03796533
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Hematology department, Pierre-Bénite, France
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Intrathecal (IT) triple chemotherapy prophylaxis
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT03793478
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- Conditions
- Refractory Acute Myeloid Leukemia (AML)Relapsed Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Opna Bio LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03787498
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Comprehensive Cancer At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸NewYork-Presbyterian / Weill Cornell Medical Center, New York, New York, United States
Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib
- Conditions
- Acute Myeloid Leukemia With Gene Mutations
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT03746912
A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT03730012
- Locations
- 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT03723681
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03709576
- Locations
- 🇺🇸
Penn State Hershey Medical Center: Penn State Cancer Institute, Hershey, Pennsylvania, United States